Budget Impact Analysis of Breast Cancer in The Russian Federation

• Autorzy: Pavel Vorobiev , Liubov Krasnova , Malwina Holownia
• Języki publikacji: EN

Abstrakty

EN

Breast cancer is one of the leading causes of cancer-related morbidity and mortality in the female population of the Russia and its incidence is rapidly growing. Advanced breast cancer is a disease currently intreatable, but up-to-date management strategies result in significant improvement of symptoms, life expectancy and quality of life. Implementation of new technologies always results in extended healthcare expenditures, therefore requiring pharmacoeconomical justification. Russian Society for Pharmacoeconomics and Outcomes Research performed health economics evaluation of typical management strategies of patients with advanced hormone-dependent HER2-negative breast cancer, based on survey of experts. The questionnaire developed for this purpose including data relevant to epidemiological and pharmacoeconomic assessment of management of such patients. Calculation of expenses incurred by medications and medical care was performed based on experts' data and according to the medical care standard

Słowa kluczowe

EN

Cancer; State budget; Medical treatment

PL

Choroby nowotworowe; Budżet państwa; Leczenie

• Czasopismo: Journal of Health Policy and Outcomes Research
• Rocznik: 2016
• Numer: nr 1
• Strony: 30--36

Twórcy

autor

Pavel Vorobiev

• Russian Society for Pharmacoeconomics and Outcomes Research

autor

Liubov Krasnova

• Russian Society for Pharmacoeconomics and Outcomes Research

autor

Malwina Holownia

• Russian Society for Pharmacoeconomics and Outcomes Research

Bibliografia

• Carrick S, Parker S, Thornton CE et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD003372
• National Cancer Institute. SEER Cancer Statistics Review 1975-2008. SEER, 2011. http://seer.cancer.gov/csr/1975_2008/. Accessed October 24, 2011
• Johnston S. New strategies in estrogen receptor-positive breast cancer. Clin. Cancer Res. 2010;16:1979-87
• Semiglazov VF, Dashyan GA, Semiglazov VV, et al. Targetnaya terapiya raka molochnoy zhelezy (novyye napravleniya)// Farmateka, 2011. - №7:p.14-20
• Lane HA, Wood JM, McSheehy PM et al. MTOR inhibitor RAD001 (Everolimus) has antiangio-genic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009;15:1612-22
• Gnant M, et al. Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2 // JNCI (2013), Vol. 105, Issue 9: 654-663
• Yardley DA. Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions. Breast Cancer: Basic and Clinical Research 2013:7 7-22
• O'Regan R, Ozguroglu M, Andre F, et al. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3) J Clin Oncol. 2013;31(Suppl) Abstr 505
• Treilleux I, Arnedos M, Cropet C, et al. Predictive markers of everolimus efficacy in hormone receptor positive (HR+) metastatic breast cancer (MBC): final results of the TAMRAD trial translational study. J Clin Oncol. 2013;31(Suppl) Abstr 510
• Xie J et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer inthe United States // Journal of Medical Economics, Vol. 16, No. 2, 2013, 278-288
• Vorobiev PA, Avksentyeva MV, Borisenko OB, et al. Kliniko-ekonomicheskiy analiz. Edited by P.A.Vorobiev. - M., Publishing house: «Newdiamed». - 2008. - 778 p
• Zlokachestvennyye novoobrazovaniya v Rossii v 2012 godu (zabolevayemost' i smertnost') / Edited by V.I. Chissov, V.V. Starinskyi, G.V. Petrovaya // M.: FGBU «MNIOI named after P.A. Gertsen» of Russian Ministry of Health. - 2012. - il. - 289 sp
• Sostoyaniye onkologicheskoy pomoshchi naseleniyu Rossii v 2012 godu / Edited by A.D. Kaprin, V.V. Starinskyi, G.V. Petrovaya // M.: FGBU «MNIOI named after P.A. Gertsen» of Russian Ministry of Health, 2013. - il. - 232 p
• Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced. European Journal of Cancer 1999;35(8):1194-1201
• Burris HA, Lebrun F, Rugo HS, et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the Phase 3, randomized, controlled, BOLERO-2 trial. Cancer. 2013;119:1908-1915

Identyfikatory

DOI

10.7365/JHPOR.2016.1.5